Investors & News

Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$28.20
Change (%) Stock is Up 0.43 (1.55%)
Volume14,042
Data as of 04/25/17 1:45 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $28.20 with a 52 week high of $30.57 and a 52 week low of $11.92.
Recent NewsMore >>
03/Apr/2017
Ascendis Pharma A/S Showcases New Data on Rare Disease Product Pipeline at ENDO 2017
31/Mar/2017
Ascendis Pharma A/S Announces Updated Time for April 3 Conference Call to Review ENDO 2017 Data
23/Mar/2017
Ascendis Pharma A/S Announces Conference Call and Webcast to Review Data at ENDO 2017 on April 3
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma
E-mail: ir@ascendispharma.com

Data provided by Nasdaq. Minimum 15 minutes delayed.